Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Return on Capital Employed (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Return on Capital Employed for 8 consecutive years, with 0.66% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 19.0% to 0.66% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.66%, a 19.0% increase, with the full-year FY2024 number at 0.8%, down 26.0% from a year prior.
  • Return on Capital Employed was 0.66% for Q3 2025 at Whitehawk Therapeutics, down from 0.52% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.11% in Q1 2021 to a low of 1.11% in Q4 2024.
  • A 5-year average of 0.64% and a median of 0.66% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -98bps in 2021, then surged 66bps in 2022.
  • Whitehawk Therapeutics' Return on Capital Employed stood at 0.75% in 2021, then skyrocketed by 51bps to 0.37% in 2022, then tumbled by -78bps to 0.66% in 2023, then plummeted by -69bps to 1.11% in 2024, then soared by 40bps to 0.66% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Return on Capital Employed are 0.66% (Q3 2025), 0.52% (Q2 2025), and 0.45% (Q1 2025).